Literature DB >> 1908968

Longitudinal followup of patients with Menière's disease.

J D Green1, D J Blum, S G Harner.   

Abstract

The etiology, pathophysiology, and natural history of Menière's syndrome are poorly understood. The reported studies have had inadequate followup or insufficient numbers of patients to allow conclusions about the natural history. Our study group was 119 patients who had the classic symptom complex of episodic vertigo, tinnitus, and hearing loss in the year 1970. After initial review of these charts, follow-up information was obtained by questionnaire, telephone interview, chart review, or repeat examination, when possible, both in 1983 and in 1988, for a total followup of 18 years. In the patients with followups of at least 14 years, vertiginous episodes had disappeared completely in 50% of patients and somewhat resolved in 28%; hearing was absent in 48% and worse in 21%. Surprisingly, 43% of patients underwent surgery at some point for control of vertigo. Bilateral disease was present initially in 13% and developed subsequently in 45% of patients. Other areas reviewed included the efficacy of long-term medical treatment, frequency and severity of vertiginous attacks, and contralateral ear symptoms.

Entities:  

Mesh:

Year:  1991        PMID: 1908968     DOI: 10.1177/019459989110400603

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  13 in total

1.  Vestibular evoked myogenic potentials (VEMP) can detect asymptomatic saccular hydrops.

Authors:  Ming-Yee Lin; Ferdinand C A Timmer; Brad S Oriel; Guangwei Zhou; John J Guinan; Sharon G Kujawa; Barbara S Herrmann; Saumil N Merchant; Steven D Rauch
Journal:  Laryngoscope       Date:  2006-06       Impact factor: 3.325

2.  Chiropractic management of a 40-year-old female patient with Ménière disease.

Authors:  Peter C Emary
Journal:  J Chiropr Med       Date:  2010-03

3.  Clinical Value of Vestibular Evoked Myogenic Potential in Assessing the Stage and Predicting the Hearing Results in Ménière's Disease.

Authors:  Min-Beom Kim; Jeesun Choi; Ga Young Park; Yang-Sun Cho; Sung Hwa Hong; Won-Ho Chung
Journal:  Clin Exp Otorhinolaryngol       Date:  2013-06-14       Impact factor: 3.372

4.  Vestibulo-Cochlear Function After Cochlear Implantation in Patients With Meniere's Disease.

Authors:  Raquel Manrique-Huarte; Diego Calavia; Laura Alvarez-Gomez; Alicia Huarte; Nicolás Perez-Fernández; Manuel Manrique
Journal:  J Int Adv Otol       Date:  2018-04       Impact factor: 1.017

5.  Glycerol pure tone audiometry and glycerol vestibular evoked myogenic potential: representing specific status of endolymphatic hydrops in the inner ear.

Authors:  Jae Ho Ban; Jong Kyu Lee; Sung Min Jin; Kyung Chul Lee
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-06-28       Impact factor: 2.503

Review 6.  Idiopathic sensorineural hearing disorders in adults--a pragmatic approach.

Authors:  David L George; Sagun Pradhan
Journal:  Nat Rev Rheumatol       Date:  2009-08-04       Impact factor: 20.543

7.  Menière's disease treated by grommet insertion.

Authors:  R G Kanegaonkar; A Najuko-Mafemera; R Hone; T Tikka
Journal:  Ann R Coll Surg Engl       Date:  2019-09-11       Impact factor: 1.891

8.  High prevalence of systemic autoimmune diseases in patients with Menière's disease.

Authors:  Irene Gazquez; Andres Soto-Varela; Ismael Aran; Sofia Santos; Angel Batuecas; Gabriel Trinidad; Herminio Perez-Garrigues; Carlos Gonzalez-Oller; Lourdes Acosta; Jose A Lopez-Escamez
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

9.  Characteristics of the Cochlear Symptoms and Functions in Meniere's Disease.

Authors:  Yi Zhang; Bo Liu; Rui Wang; Ruo Jia; Xin Gu
Journal:  Chin Med J (Engl)       Date:  2016-10-20       Impact factor: 2.628

10.  Abnormal Cervical Vestibular-Evoked Myogenic Potentials Predict Evolution of Isolated Recurrent Vertigo into Meniere's Disease.

Authors:  Sun-Uk Lee; Hyo-Jung Kim; Jeong-Yoon Choi; Ja-Won Koo; Ji-Soo Kim
Journal:  Front Neurol       Date:  2017-09-04       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.